Sophie Peigné, Ph.D.

Senior Consultant

Portrait-of-Sophie-Peigne-Pharmetheus

Bio

  • Joined Pharmetheus in 2022, actively working in client projects
  • Expertise includes clinical pharmacokinetics, pediatric drug development, in-vitro in-vivo correlation, and pharmacometrics in therapeutic areas such as oncology, immuno-oncology, cardiology, and neurology
  • Previously worked as PK Project Manager and Principal Pharmacometrician at Servier, France
  • Pharm.D. (2010), Master Degree in Pharmacokinetics (2010), and Ph.D. in Pharmacometrics (2015) from the University of Paris V, France
LinkedInGoogle Scholar

Pharmetheus affiliated publications

Population Pharmacokinetic Analysis of Datopotamab Deruxtecan (Dato-DXd), a TROP2-Directed Antibody-Drug Conjugate, in Patients With Advanced Solid TumorsExposure-efficacy analysis of datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, in patients with advanced non-small cell lung cancerPopulation pharmacokinetic analysis of Datopotamab deruxtecan (Dato-DXd), a TROP2-targeting antibody-drug conjugate